Patent Awarded
|
|
Pacific Edge Biotechnology Limited (PEB) | 4:48 pm, Monday 17 December 2007 | PEB | 0.100 |
 0 |
(+0.00%) |
Pacific Edge Awarded Third US Patent for Cancer Diagnostic and Prognostic
Software
Pacific Edge has recently been awarded a United States patent for the third
of three patent applications covering their proprietary software and
algorithm development. This software was developed by one of the Company's
founders Professor Nik Kasabov.
The software enables the evaluation and modeling of large patient databases
to develop personalised models for the better determination of patient
diagnosis and prognosis. Based on fuzzy logic and neural networks the
software enables the Company to interpret complex patterns of gene expression
that define the biological processes involved in the initiation and
development of cancer. The software has potential in other medical fields
such as modeling of data from Mass Spectroscopy.
It is anticipated that there are likely to be a number of companies and
organisations, around the world already using the technology contained in the
Company's newly issued patents and that these companies are likely to need to
seek a commercial license from the Company.
Pacific Edge was awarded a United States patent in August 2006 for Adaptive
Learning System and Method and this has been followed, in February 2007 with
the New Zealand patent office issuing the Company a patent for 'Medical
Applications of Adaptive Learning Systems Using Gene Expression Data'. This
patent has now also been issued in the US by the US Patent Office.
Prof. Nik Kasabov is the founding director and Chief Scientist of the
Knowledge Engineering and Discovery Research Institute, KEDRI and is the
Chair of Knowledge Engineering, School of Computing and Information Sciences
at the Auckland University of Technology.
Pacific Edge Biotechnology Limited (PEB) is a Dunedin based biomedical
company developing and commercialising technology for cancer detection and
management.
For further information please contact;
David Darling or Prof. Nik Kasabov
Chief Executive Officer Chief Scientist, KEDRI.
Pacific Edge Biotechnology Ltd Auckland University of Technology
E: david.darling@peblnz.com nkasabov@aut.ac.nz
P: 03 479 5800 09 921 9506
C: 021 797 981 021 488 214
